CJC-1295 (no DAC) + Ipamorelin Blend

This is a demonstration store. You can purchase products like this from Versed.

Lyophilized CJC (No DAC) + Ipamorelin Blend

Overview

CJC‑1295 (No DAC) is a synthetic GHRH analogue (amino acids 1–29) that triggers GH secretion via pituitary GHRH receptors, clearing rapidly (half‑life ~30 min) to mimic physiological pulse patterns. Ipamorelin is a pentapeptide GHS (Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂) that binds ghrelin receptors to release GH with high specificity and minimal side effects, featuring a ~2 hr half‑life. When co‑administered, they produce additive and sustained GH and IGF‑1 responses, ideal for research into anabolic signaling, metabolic regulation, and endocrine feedback PubMed.

Key Features

• Dual‑Receptor Engagement: CJC‑1295 (No DAC) targets GHRH receptors; Ipamorelin engages ghrelin receptors—together amplifying GH release more than either alone.

• Synergistic GH & IGF‑1 Elevation: Combines CJC‑1295’s pulsatile GH trigger with Ipamorelin’s sustained secretagogue action to achieve dose‑dependent, multi‑day IGF‑1 increases Regulations.govPubMed.

• Optimized Pharmacokinetics: CJC‑1295 (No DAC) clears in ~30 min, allowing for discrete GH pulses; Ipamorelin’s ~2 hr half‑life extends the GH‑releasing window without receptor desensitization.

• High Purity & Stability: Lyophilized blend verified ≥ 99 % purity by reverse‑phase HPLC; freeze‑dried format ensures long shelf life and rapid reconstitution.

• Defined Ratios: Commonly supplied as equimolar concentrations (e.g., 1 mg CJC‑1295 + 1 mg Ipamorelin per mL), enabling precise dose titration for in vitro and in vivo studies Regulations.gov.

Mechanism of Action

CJC‑1295 (No DAC)

• GHRH Receptor Agonist: Binds to somatotroph GHRH receptors in the anterior pituitary, eliciting GH release in a natural pulsatile pattern.

• Short Half‑Life: Rapid clearance (~30 min) prevents prolonged receptor occupancy, maintaining physiological feedback loops.

Ipamorelin

• Ghrelin Receptor Selective: Stimulates the GHS‑R1a receptor without significant impacts on cortisol or prolactin, minimizing off‑target effects ResearchGatePubMed.

• Prolonged Secretagogue Action: Half‑life ~2 hr sustains GH output, extending the anabolic window created by CJC‑1295 pulses ResearchGate.

Applications

• Endocrine Research: Model GH/IGF‑1 axis dynamics, feedback regulation, and receptor pharmacology in cell and animal studies PubMed.

• Muscle Anabolism & Regeneration: Probe GH‑driven signaling in myoblast differentiation, protein synthesis, and repair mechanisms Oxford Academic.

• Metabolic Studies: Investigate effects on lipolysis, glucose homeostasis, and energy expenditure pathways.

• Peptide Delivery Research: Evaluate combination dosing, pharmacokinetics, and release kinetics in formulation and kinetics experiments Regulations.gov.

Specifications